BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 10554052)

  • 1. A risk-benefit assessment of amifostine in cytoprotection.
    Mabro M; Faivre S; Raymond E
    Drug Saf; 1999 Nov; 21(5):367-87. PubMed ID: 10554052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
    Culy CR; Spencer CM
    Drugs; 2001; 61(5):641-84. PubMed ID: 11368288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential of amifostine: from cytoprotectant to therapeutic agent.
    Santini V; Giles FJ
    Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amifostine in clinical oncology: current use and future applications.
    Koukourakis MI
    Anticancer Drugs; 2002 Mar; 13(3):181-209. PubMed ID: 11984063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amifostine: chemotherapeutic and radiotherapeutic protective effects.
    Santini V
    Expert Opin Pharmacother; 2001 Mar; 2(3):479-89. PubMed ID: 11336600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):3-21. PubMed ID: 10348255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation.
    Hartmann JT; von Vangerow A; Fels LM; Knop S; Stolte H; Kanz L; Bokemeyer C
    Br J Cancer; 2001 Feb; 84(3):313-20. PubMed ID: 11161394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.
    Links M; Lewis C
    Drugs; 1999 Mar; 57(3):293-308. PubMed ID: 10193684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study.
    De Souza CA; Santini G; Marino G; Nati S; Congiu AM; Vigorito AC; Damasio E
    Braz J Med Biol Res; 2000 Jul; 33(7):791-8. PubMed ID: 10881054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
    Hensley ML; Schuchter LM; Lindley C; Meropol NJ; Cohen GI; Broder G; Gradishar WJ; Green DM; Langdon RJ; Mitchell RB; Negrin R; Szatrowski TP; Thigpen JT; Von Hoff D; Wasserman TH; Winer EP; Pfister DG
    J Clin Oncol; 1999 Oct; 17(10):3333-55. PubMed ID: 10506637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy.
    Capizzi RL; Scheffler BJ; Schein PS
    Cancer; 1993 Dec; 72(11 Suppl):3495-501. PubMed ID: 8242582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amifostine: A selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity (Review).
    Orditura M; De Vita F; Roscigno A; Infusino S; Auriemma A; Iodice P; Ciaramella F; Abbate G; Catalano G
    Oncol Rep; 1999; 6(6):1357-62. PubMed ID: 10523712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection of normal tissues from radiation and cytotoxic therapy: the development of amifostine.
    Castiglione F; Dalla Mola A; Porcile G
    Tumori; 1999; 85(2):85-91. PubMed ID: 10363072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing the toxicity of anticancer therapy: new strategies.
    Griggs JJ
    Leuk Res; 1998 May; 22 Suppl 1():S27-33. PubMed ID: 9734697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials.
    Capizzi RL; Oster W
    Int J Hematol; 2000 Dec; 72(4):425-35. PubMed ID: 11197208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma.
    Rose PG
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):83-9. PubMed ID: 8783673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol).
    Capizzi RL
    Eur J Cancer; 1996; 32A Suppl 4():S5-16. PubMed ID: 8976816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
    Kurbacher CM; Mallmann PK
    Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.
    Spencer CM; Goa KL
    Drugs; 1995 Dec; 50(6):1001-31. PubMed ID: 8612469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future development of amifostine as a radioprotectant.
    Werner-Wasik M
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.